NA
TERN

NewEdge Advisors’s Terns Pharmaceuticals TERN Stock Holding History

NewEdge Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,173
Closed -$371K – 4390
2025
Q4 		$371K Buy
9,173
+6,475
+240% +$150K ﹤0.01% 2172
2025
Q3 		$20.3K Hold
2,698
– – ﹤0.01% 3120
2025
Q2 		$10.1K Buy
+2,698
New +$8.43K ﹤0.01% 3215

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

NewEdge Advisors's TERN Position: Q1 2026 in Review

NewEdge Advisors sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 9,173 shares — an estimated $371K sold.

NewEdge Advisors first reported a position in TERN in Q2 2025 and held it in 3 quarters. The position peaked at $371K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • NewEdge Advisors reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 9,173 Terns Pharmaceuticals shares in Q1 2026, an estimated $371K.
  • NewEdge Advisors first reported a position in Terns Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • NewEdge Advisors's Terns Pharmaceuticals position peaked at $371K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.